Colombia's Shot at Sovereignty: A New Era in Vaccine Production

INCHEON, South Korea – May 26, 2026 – Colombia has taken a monumental step toward reclaiming its health sovereignty, signing a landmark agreement with South Korean biotech firm SK bioscience to establish local vaccine manufacturing capabilities. The deal, centered on a technology transfer to the state-owned pharmaceutical company VECOL, is the cornerstone of a US$260 million national initiative designed to end decades of reliance on foreign vaccine imports and fortify the nation against future public health crises.

The partnership will initially focus on producing SKYVaricella, SK bioscience's proprietary chickenpox vaccine, within Colombia. This collaboration marks a strategic entry into the burgeoning Latin American market for the Korean company and a transformative moment for Colombia's public health infrastructure, which has not produced new vaccines locally since 1998.

A Nation's Quest for Health Independence

The COVID-19 pandemic exposed the fragility of global supply chains and left many nations, including Colombia, vulnerable. In response, the Colombian government has launched an ambitious 10-year, US$260 million national vaccine localization project, jointly led by the Ministry of Health and Social Protection, the National Health Institute (INS), and VECOL. The objective is clear: build a resilient, self-sufficient public health system.

This initiative represents a deliberate reversal of a long-standing trend. Changes in international regulations in the late 1990s made it prohibitively expensive for Colombia to upgrade its existing facilities, leading to a complete dependence on imported vaccines for its comprehensive National Immunization Program (NIP). This new investment signals a renewed commitment to domestic scientific and industrial capacity.

Colombia's Ministry of Health and Social Protection highlighted that the agreement marks a strategic milestone that goes beyond mere production. The ministry emphasized it reflects a commitment to rebuilding domestic capabilities to respond to health challenges with "greater autonomy." The collaboration is expected to strengthen research, innovation, and local manufacturing, reducing external dependencies and creating sustainable long-term benefits.

This national drive aligns with a broader regional movement. The Pan American Health Organization (PAHO) has been a vocal proponent of strengthening local production to enhance health security across the Americas. Gina Tambini Gómez, PAHO/WHO Representative in Colombia, praised the agreement, stating, "We recognize Colombia's decision to advance toward health sovereignty... This step contributes to the commitment adopted by the Member States of the Americas to strengthen regional production capacities for health technologies."

SK bioscience's 'Glocalization' Gambit Pays Off

For SK bioscience, this partnership is a textbook execution of its 'Glocalization' strategy—a model that combines its global vaccine development and manufacturing prowess with localized production partnerships in key regions. The company's goal is to expand its global footprint by transferring technology and building capacity in nations with a need for enhanced vaccine infrastructure.

This approach has been successfully deployed elsewhere. In 2023, SK bioscience signed a similar agreement with Thailand's Government Pharmaceutical Organization (GPO) to transfer technology for its cell culture-based influenza vaccine, SKYCellflu. That deal, like the one in Colombia, aims to establish a regional production hub and strengthen pandemic preparedness.

The Colombian government's decision to partner with SK bioscience came after an exhaustive four-year review of multiple global vaccine manufacturers. SK bioscience's world-class manufacturing capabilities, portfolio of WHO Prequalified (PQ) vaccines, and proven experience in international public procurement were key factors in its selection. The company has been a trusted supplier to PAHO since 2022, with its supply contract for SKYVaricella recently extended through 2027, demonstrating the product's competitiveness.

"We are honored to participate in this national initiative led by the Colombian government and VECOL to strengthen vaccine manufacturing capabilities," said Jaeyong Ahn, President and CEO of SK bioscience. "Leveraging SK bioscience's accumulated expertise... we will continue striving to contribute to future pandemic preparedness and the establishment of a sustainable vaccine supply foundation in Latin America and beyond."

From Animal Health to Human Vaccines: The VECOL Transformation

At the heart of Colombia's strategy is VECOL S.A., a state-owned company with over seven decades of history, primarily recognized for its leadership in animal health and biotechnology products. Now, VECOL is tasked with leading one of the country's most significant scientific initiatives: spearheading the return of human vaccine production to Colombian soil.

Under the agreement, VECOL will oversee the establishment and operation of the new manufacturing facilities, manage government licensing, and ensure the locally produced vaccines are integrated into the country's NIP. SK bioscience will provide the critical technology transfer, including the know-how for facility design, product introduction, regulatory approvals with Colombia's National Institute for Food and Drug Surveillance (INVIMA), and ongoing production operations.

The selection of SKYVaricella as the inaugural product is strategic. The vaccine obtained WHO PQ certification in 2019, a globally recognized seal of quality that facilitates its inclusion in national programs. The Colombian Ministry of Health has already committed to switching all 950,000 doses of varicella vaccines for this year's NIP to SKYVaricella, ensuring immediate demand and a smooth integration pathway.

Lucía Ayala, President of VECOL, framed the partnership as a foundational shift for the nation. "This agreement represents a transformative step for the country and for strengthening our scientific and technological capabilities," she stated. "Beyond biotechnology transfer, we are building knowledge, developing capabilities, and laying the foundation for Colombia to move forward with a long-term vision toward recovering strategic capacities in public health and health sovereignty."

Remaking Latin America's Vaccine Map

The SK bioscience-VECOL partnership is poised to send ripples across Latin America's pharmaceutical landscape. Colombia is the region's third-largest pharmaceutical market, with projected sales expected to reach US$11.5 billion by 2028. This initiative positions the country to become a regional hub for vaccine production, leveraging its strategic location and well-developed healthcare system.

The collaboration addresses a critical lesson from the pandemic: the need to decentralize vaccine manufacturing. While countries like Brazil are established global suppliers, this deal helps diversify production and build a more resilient regional network, with Mexico and Argentina also pursuing local manufacturing strategies. By fostering local expertise and infrastructure, the project contributes directly to global health equity.

For SK bioscience, the agreement is more than just a single contract; it is a strategic foothold. The company has secured preferential negotiation rights for future vaccines to be produced at the new facility, including its own proprietary products and others adopted by the Colombian government. This ensures a long-term presence and a significant role in shaping the future of public health in one of the world's most dynamic and rapidly growing regions.